(ON-DEMAND ACOI 2024) The Art of Reducing Progression of Chronic Kidney Disease

CME Credit Available:

This activity offers .5 1A AOA 

Note: ACOI reports credits to the AOA at the beginning of each month.

Learning Objectives:

In this session, you'll learn how to:

• Evaluate the efficacy of pharmacological interventions such as ACE-i, ARB, MCA, SGLT-2, GLP agonist in relation to slowing the progression of chronic kidney disease.
• Implement multimodal approaches for chronic kidney disease management, explore the benefits of integrated strategies including blood pressures reduction, dietary protein restriction and bicarbonate therapies, in conjunction with pharmacotherapies.
• Translate evidence-based guidelines into clinical practice, analysis the current KDIGO guidelines for the management of chronic kidney disease in diverse patient populations.

Conflict of Interest Disclosures: 

ACOI requires each planner and presenter to identify all conflicts of interest and mitigates risk of bias using a series of strategies for relevant conflicts. Unless otherwise noted below, the ACOI, ACOI staff and planners for this activity have no relevant financial relationships with ineligible companies to disclose.

David I. Somerman, DO, FACOI, faculty for this activity, has no relevant relationships with ineligible companies to disclose. 

Release & Review Date: 

This activity is valid from January 1, 2025, until January 1, 2028.